경희대학교 student startup team Tabtension (CEO Kim Yoo-chan) has begun developing an auxiliary diagnostic technology that identifies high-risk groups for ADHD using tablet touch data. CEO Kim explained that the startup was motivated by his experience studying in the Daechi-dong private education district in Seoul, where ADHD medications were mistakenly perceived as “study enhancement drugs” and were misused by some students.

Tabtension announced that it has been selected for the “2026 Public Technology-based Company Builder (COMPA)” program operated by KIST Innovation, a technology commercialization specialist company of the Korea Institute of Science and Technology (KIST). Through this selection, the team will receive support for advancing its business model, establishing an intellectual property (IP) strategy, and securing commercialization funding. Around the same time, it was also chosen for the 6th cohort of the technology startup accelerating program “2026 GRaND-K Startup School” and advanced to the final round of the startup competition.

The service under development analyzes touch behavior displayed while users perform a tablet-based task of approximately 10 minutes using machine learning. Based on this, the goal is to detect high-risk groups for ADHD at an early stage and provide reference information for medical professionals during diagnosis. Tabtension is currently based at the Hongneung Bio & Medical Startup Center within the Hongneung Innopolis and is preparing to establish a corporation.

CEO Kim stated that the company aims to develop a medical device that supports, rather than replaces, specialist diagnoses and expressed a desire to contribute to resolving the problem of medication misuse. Tabtension plans to proceed with market validation alongside clinical research and other empirical studies.

Popular News